• Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial. 

  Rodriguez Gutierrez, D; Jones, C; Varlet, P; Mackay, A; Warren, D; Warmuth-Metz, M; Sánchez Aliaga, E; Calmon, R; Hargrave, DR; Cañete, A; Massimino, M; Azizi, AA; Le Deley, M-C; Saran, F; Rousseau, RF; Zahlmann, G; Garcia, J; Vassal, G; Grill, J; Morgan, PS; Jaspan, T (2020-01-10)

  BACKGROUND:The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/Temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma ...
• Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. 

  Mandelker, D; Donoghue, M; Talukdar, S; Bandlamudi, C; Srinivasan, P; Vivek, M; Jezdic, S; Hanson, H; Snape, K; Kulkarni, A; Hawkes, L; Douillard, J-Y; Wallace, SE; Rial-Sebbag, E; Meric-Bersntam, F; George, A; Chubb, D; Loveday, C; Ladanyi, M; Berger, MF; Taylor, BS; Turnbull, C (2019-08)

  It is increasingly common in oncology practice to perform tumour sequencing using large cancer panels. For pathogenic sequence variants in cancer susceptibility genes identified on tumour-only sequencing, it is often unclear ...
• Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study. 

  Forster, MD; Dillon, MT; Kocsis, J; Remenár, É; Pajkos, G; Rolland, F; Greenberg, J; Harrington, KJ (2019-12)

  BACKGROUND:The fully human monoclonal antibody patritumab blocks HER3 activation, a resistance mechanism to cetuximab, induced by heregulin (HRG). A phase Ib study in recurrent and/or metastatic (R/M) squamous cell carcinoma ...
• APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. 

  Driscoll, CB; Schuelke, MR; Kottke, T; Thompson, JM; Wongthida, P; Tonne, JM; Huff, AL; Miller, A; Shim, KG; Molan, A; Wetmore, C; Selby, P; Samson, A; Harrington, K; Pandha, H; Melcher, A; Pulido, JS; Harris, R; Evgin, L; Vile, RG (2020-02-07)

  APOBEC3B, an anti-viral cytidine deaminase which induces DNA mutations, has been implicated as a mediator of cancer evolution and therapeutic resistance. Mutational plasticity also drives generation of neoepitopes, which ...
• Loss of 5'-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness. 

  Menezes, WPD; Silva, VAO; Gomes, INF; Rosa, MN; Spina, MLC; Carloni, AC; Alves, ALV; Melendez, M; Almeida, GC; Silva, LSD; Clara, C; da Cunha, IW; Hajj, GNM; Jones, C; Bidinotto, LT; Reis, RM (2020-02-20)

  The 5'-methylthioadenosine phosphorylase (MTAP) gene is located in the chromosomal region 9p21. MTAP deletion is a frequent event in a wide variety of human cancers; however, its biological role in tumorigenesis remains ...
• Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. 

  Feng, H; Gusev, A; Pasaniuc, B; Wu, L; Long, J; Abu-Full, Z; Aittomäki, K; Andrulis, IL; Anton-Culver, H; Antoniou, AC; Arason, A; Arndt, V; Aronson, KJ; Arun, BK; Asseryanis, E; Auer, PL; Azzollini, J; Balmaña, J; Barkardottir, RB; Barnes, DR; Barrowdale, D; Beckmann, MW; Behrens, S; Benitez, J; Bermisheva, M; Białkowska, K; Blanco, A; Blomqvist, C; Boeckx, B; Bogdanova, NV; Bojesen, SE; Bolla, MK; Bonanni, B; Borg, A; Brauch, H; Brenner, H; Briceno, I; Broeks, A; Brüning, T; Burwinkel, B; Cai, Q; Caldés, T; Caligo, MA; Campbell, I; Canisius, S; Campa, D; Carter, BD; Carter, J; Castelao, JE; Chang-Claude, J; Chanock, SJ; Christiansen, H; Chung, WK; Claes, KBM; Clarke, CL; GEMO Study Collaborators; EMBRACE Collaborators; GC-HBOC study Collaborators; Couch, FJ; Cox, A; Cross, SS; Cybulski, C; Czene, K; Daly, MB; de la Hoya, M; De Leeneer, K; Dennis, J; Devilee, P; Diez, O; Domchek, SM; Dörk, T; Dos-Santos-Silva, I; Dunning, AM; Dwek, M; Eccles, DM; Ejlertsen, B; Ellberg, C; Engel, C; Eriksson, M; Fasching, PA; Fletcher, O; Flyger, H; Fostira, F; Friedman, E; Fritschi, L; Frost, D; Gabrielson, M; Ganz, PA; Gapstur, SM; Garber, J; García-Closas, M; García-Sáenz, JA; Gaudet, MM; Giles, GG; Glendon, G; Godwin, AK; Goldberg, MS; Goldgar, DE; González-Neira, A; Greene, MH; Gronwald, J; Guénel, P; Haiman, CA; Hall, P; Hamann, U; Hake, C; He, W; Heyworth, J; Hogervorst, FBL; Hollestelle, A; Hooning, MJ; Hoover, RN; Hopper, JL; Huang, G; Hulick, PJ; Humphreys, K; Imyanitov, EN; ABCTB Investigators; HEBON Investigators; BCFR Investigators; OCGN Investigators; Isaacs, C; Jakimovska, M; Jakubowska, A; James, P; Janavicius, R; Jankowitz, RC; John, EM; Johnson, N; Joseph, V; Jung, A; Karlan, BY; Khusnutdinova, E; Kiiski, JI; Konstantopoulou, I; Kristensen, VN; Laitman, Y; Lambrechts, D; Lazaro, C; Leroux, D; Leslie, G; Lester, J; Lesueur, F; Lindor, N; Lindström, S; Lo, W-Y; Loud, JT; Lubiński, J; Makalic, E; Mannermaa, A; Manoochehri, M; Manoukian, S; Margolin, S; Martens, JWM; Martinez, ME; Matricardi, L; Maurer, T; Mavroudis, D; McGuffog, L; Meindl, A; Menon, U; Michailidou, K; Kapoor, PM; Miller, A; Montagna, M; Moreno, F; Moserle, L; Mulligan, AM; Muranen, TA; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Nevelsteen, I; Nielsen, FC; Nikitina-Zake, L; Offit, K; Olah, E; Olopade, OI; Olsson, H; Osorio, A; Papp, J; Park-Simon, T-W; Parsons, MT; Pedersen, IS; Peixoto, A; Peterlongo, P; Peto, J; Pharoah, PDP; Phillips, K-A; Plaseska-Karanfilska, D; Poppe, B; Pradhan, N; Prajzendanc, K; Presneau, N; Punie, K; Pylkäs, K; Radice, P; Rantala, J; Rashid, MU; Rennert, G; Risch, HA; Robson, M; Romero, A; Saloustros, E; Sandler, DP; Santos, C; Sawyer, EJ; Schmidt, MK; Schmidt, DF; Schmutzler, RK; Schoemaker, MJ; Scott, RJ; Sharma, P; Shu, X-O; Simard, J; Singer, CF; Skytte, A-B; Soucy, P; Southey, MC; Spinelli, JJ; Spurdle, AB; Stone, J; Swerdlow, AJ; Tapper, WJ; Taylor, JA; Teixeira, MR; Terry, MB; Teulé, A; Thomassen, M; Thöne, K; Thull, DL; Tischkowitz, M; Toland, AE; Tollenaar, RAEM; Torres, D; Truong, T; Tung, N; Vachon, CM; van Asperen, CJ; van den Ouweland, AMW; van Rensburg, EJ; Vega, A; Viel, A; Vieiro-Balo, P; Wang, Q; Wappenschmidt, B; Weinberg, CR; Weitzel, JN; Wendt, C; Winqvist, R; Yang, XR; Yannoukakos, D; Ziogas, A; Milne, RL; Easton, DF; Chenevix-Trench, G; Zheng, W; Kraft, P; Jiang, X (2020-03)

  Previous transcriptome-wide association studies (TWAS) have identified breast cancer risk genes by integrating data from expression quantitative loci and genome-wide association studies (GWAS), but analyses of breast cancer ...
• Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. 

  Grünwald, V; Chirovsky, D; Cheung, WY; Bertolini, F; Ahn, M-J; Yang, M-H; Castro, G; Berrocal, A; Sjoquist, K; Kuyas, H; Auclair, V; Guillaume, X; Joo, S; Shah, R; Harrington, K; GLANCE H&N STUDY Investigators (2020-01-21)

  OBJECTIVES:Given a lack of universally-accepted standard-of-care treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), study objectives were to assess treatment utilization and ...
• Genetic predisposition for multiple myeloma. 

  Pertesi, M; Went, M; Hansson, M; Hemminki, K; Houlston, RS; Nilsson, B (2020-03)

  Multiple myeloma (MM) is the second most common blood malignancy. Epidemiological family studies going back to the 1920s have provided evidence for familial aggregation, suggesting a subset of cases have an inherited genetic ...
• Topological Tumor Graphs: a graph-based spatial model to infer stromal recruitment for immunosuppression in melanoma histology. 

  Failmezger, H; Muralidhar, S; Rullan, A; de Andrea, CE; Sahai, E; Yuan, Y (2019-12-24)

  Despite the advent of immunotherapy, metastatic melanoma represents an aggressive tumor type with a poor survival outcome. The successful application of immunotherapy requires in-depth understanding of the biological basis ...
• Computational image analysis of T-cell infiltrates in resectable gastric cancer: association with survival and molecular subtypes 

  Challoner, B; von Loga, K; Woolston, A; Griffiths, B; Sivamanoharan, N; Semiannikova, M; Newey, A; Barber, L; Mansfield, D; Hewitt, L; Saito, Y; Davarzani, N; Starling, N; Melcher, A; Grabsch, H; Gerlinger, M

  Background: Gastric and gastro-oesophageal junction cancers (GCs) frequently recur after resection but markers to predict recurrence risk are missing. T-cell infiltrates have been validated as prognostic markers in other ...
• Metal-based imaging agents: progress towards interrogating neurodegenerative disease. 

  Sedgwick, AC; Brewster, JT; Harvey, P; Iovan, DA; Smith, G; He, X-P; Tian, H; Sessler, JL; James, TD (2020-03-30)

  Central nervous system (CNS) neurodegeneration is defined by a complex series of pathological processes that ultimately lead to death. The precise etiology of these disorders remains unknown. Recent efforts show that a ...
• Ten-year results of FAST: a randomised controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer 

  Bliss, J; Haviland, JS; Sydenham, M; Yarnold, J
• Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. 

  Neal, DE; Metcalfe, C; Donovan, JL; Lane, JA; Davis, M; Young, GJ; Dutton, SJ; Walsh, EI; Martin, RM; Peters, TJ; Turner, EL; Mason, M; Bollina, P; Catto, J; Doherty, A; Gillatt, D; Gnanapragasam, V; Holding, P; Hughes, O; Kockelbergh, R; Kynaston, H; Oxley, J; Paul, A; Paez, E; Rosario, DJ; Rowe, E; Staffurth, J; Altman, DG; Hamdy, FC; ProtecT Study Group (2020-03)

  BACKGROUND:The ProtecT trial reported intention-to-treat analysis of men with localised prostate cancer (PCa) randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy. OBJECTIVE:To ...
• Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. 

  Shah, V; Sherborne, AL; Johnson, DC; Ellis, S; Price, A; Chowdhury, F; Kendall, J; Jenner, MW; Drayson, MT; Owen, RG; Gregory, WM; Morgan, GJ; Davies, FE; Cook, G; Cairns, DA; Houlston, RS; Jackson, G; Kaiser, MF; on behalf of NCRI Haematology Clinical Studies Group (2020-03-11)
• CHK1 inhibition is synthetically lethal with loss of B-family DNA polymerase function in human lung and colorectal cancer cells. 

  Rogers, RF; Walton, MI; Cherry, DL; Collins, I; Clarke, PA; Garrett, MD; Workman, P (2020-03-11)

  Checkpoint kinase 1 (CHK1) is a key mediator of the DNA damage response that regulates cell cycle progression, DNA damage repair and DNA replication. Small-molecule CHK1 inhibitors sensitise cancer cells to genotoxic agents ...
• Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network. 

  Garrett, A; Callaway, A; Durkie, M; Cubuk, C; Alikian, M; Burghel, GJ; Robinson, R; Izatt, L; Talukdar, S; Side, L; Cranston, T; Palmer-Smith, S; Baralle, D; Berry, IR; Drummond, J; Wallace, AJ; Norbury, G; Eccles, DM; Ellard, S; Lalloo, F; Evans, DG; Woodward, E; Tischkowitz, M; Hanson, H; Turnbull, C; CanVIG-UK (2020-03-13)

  Advances in technology have led to a massive expansion in the capacity for genomic analysis, with a commensurate fall in costs. The clinical indications for genomic testing have evolved markedly; the volume of clinical ...
• The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study 

  van Osch, FHM; Jochems, SHJ; Reulen, RC; Pirrie, SJ; Nekeman, D; Wesselius, A; James, ND; Wallace, DMA; Cheng, KK; van Schooten, FJ; Bryan, RT; Zeegers, MP (Springer Science and Business Media LLC, 2018-07)
• What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis 

  Vale, CL; Fisher, DJ; White, IR; Carpenter, JR; Burdett, S; Clarke, NW; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LH; Sweeney, CJ; Spears, MR; Sydes, MR; Tierney, JF (Elsevier BV, 2018-05)
• Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking. 

  Cresswell, GD; Nichol, D; Spiteri, I; Tari, H; Zapata, L; Heide, T; Maley, CC; Magnani, L; Schiavon, G; Ashworth, A; Barry, P; Sottoriva, A (2020-03-27)

  Circulating tumour DNA (ctDNA) allows tracking of the evolution of human cancers at high resolution, overcoming many limitations of tissue biopsies. However, exploiting ctDNA to determine how a patient's cancer is evolving ...
• Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification 

  Snell, KIE; Ward, DG; Gordon, NS; Goldsmith, JC; Sutton, AJ; Patel, P; James, ND; Zeegers, MP; Cheng, KK; Bryan, RT (Impact Journals, LLC, 2018-05-18)

View more